Neurocrine Biosciences Company Insiders

Neurocrine Biosciences' latest congressional trading

Neurocrine Biosciences Management Team Effectiveness

The company has return on total asset (ROA) of 0.118 % which means that it generated a profit of $0.118 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1635 %, meaning that it created $0.1635 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2024. Return On Capital Employed is likely to rise to 0.10 in 2024. At this time, Neurocrine Biosciences' Fixed Asset Turnover is fairly stable compared to the past year. Return On Assets is likely to rise to 0.08 in 2024, whereas Intangibles To Total Assets are likely to drop 0.01 in 2024. Net Income Applicable To Common Shares is likely to rise to about 186.6 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 61.8 M in 2024.

Neurocrine Biosciences Workforce Comparison

The company has Profit Margin (PM) of 0.17 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.3 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.3.

Neurocrine Biosciences Insider Trading History

Neurocrine Biosciences Notable Stakeholders

The success or failure of an entity such as Neurocrine Biosciences often depends on how effective the management is. Neurocrine Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Neurocrine management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Neurocrine management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Neurocrine Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Neurocrine Biosciences. Check Neurocrine Biosciences' Beneish M Score to see the likelihood of Neurocrine Biosciences' management manipulating its earnings.

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.